Literature DB >> 9881942

Molecular characterization of CXCR-4: a potential brain tumor-associated gene.

A Sehgal1, S Ricks, A L Boynton, J Warrick, G P Murphy.   

Abstract

BACKGROUND AND OBJECTIVES: We have previously reported the isolation of a G protein-coupled receptor, CXCR-4, that is overexpressed in glioblastoma multiforme tumor tissue (GMTT), as compared to normal brain tissue (NBT).
METHODS: Gene-specific RT-PCR, Northern blotting, and in situ hybridization techniques were used to study its expression in a variety of normal tissues, tumor tissues, and cell lines, as well as during development. Antisense CXCR-4 was overexpressed in glioblastoma cells to study its effect on cell proliferation.
RESULTS: Gene-specific RT-PCR analysis indicated that the CXCR-4 gene is overexpressed in several malignant glioma tissues, breast tumor tissues and cell lines. Northern blot analysis indicated that CXCR-4 is expressed at high levels in certain leukemias, uterine cancer, and Burkitt's lymphoma cell line. The occipital and temporal lobe showed high levels of CXCR4 in normal human brain. The CXCR-4 gene was expressed in all organs in the early stages of development (days 8-10). In adult mouse, CXCR-4 is expressed only in brain, spinal cord, bone marrow, and pituitary gland. Antisense CXCR-4 overexpression in glioblastoma cells caused inhibition of cell proliferation and induction of cellular differentiation in vitro. This suggests that CXCR-4 expression may play an important role during embryonic development and also in the genesis of human gliomas.
CONCLUSIONS: On the basis of CXCR4 expression data and antisense overexpression data, we conclude that CXCR-4 plays an important role in the tumorigenic properties of brain, breast, and other tumor types. On the basis of its unique expression during mouse development, we conclude that it may play an important role in the normal functioning of brain, spinal cord, and bone marrow during development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881942     DOI: 10.1002/(sici)1096-9098(199812)69:4<239::aid-jso9>3.0.co;2-u

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

Review 1.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

Review 2.  Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.

Authors:  Meizhang Li; Richard M Ransohoff
Journal:  Prog Neurobiol       Date:  2007-11-26       Impact factor: 11.685

3.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

Authors:  Shusaku Ohira; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Yoh Zen; Kumiko Isse; Kazuto Kozaka; Akira Ishikawa; Koji Oda; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages.

Authors:  Shuzhen Chen; Daniel L Tuttle; Joseph T Oshier; Harm J Knot; Wolfgang J Streit; Maureen M Goodenow; Jeffrey K Harrison
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

5.  Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo.

Authors:  David M Goldenberg; David Zagzag; Kerstin M Heselmeyer-Haddad; Lissa Y Berroa Garcia; Thomas Ried; Meiyu Loo; Chien-Hsing Chang; David V Gold
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

6.  The SDF-1 3'A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients.

Authors:  Seyyed Reza Moosavi; Hossein Khorramdelazad; Masoud Amin; Shirin Fatahpoor; Mozhgan Moogooei; Mojgan Noroozi Karimabad; Mohamadreza Jamali Paghale; Alireza Vakilian; Gholamhossein Hassanshahi
Journal:  J Mol Neurosci       Date:  2013-01-20       Impact factor: 3.444

Review 7.  Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?

Authors:  Carine Savarin-Vuaillat; Richard M Ransohoff
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

8.  Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Authors:  Ilya V Ulasov; Matthew A Tyler; Angel A Rivera; Dirk M Nettlebeck; Joanne T Douglas; Maciej S Lesniak
Journal:  J Med Virol       Date:  2008-09       Impact factor: 2.327

9.  CXCR4/CXCL12 expression and signalling in kidney cancer.

Authors:  A J Schrader; O Lechner; M Templin; K E J Dittmar; S Machtens; M Mengel; M Probst-Kepper; A Franzke; T Wollensak; P Gatzlaff; J Atzpodien; J Buer; J Lauber
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model.

Authors:  Kang Su Cho; So Jung Yoon; Joo Yong Lee; Nam Hoon Cho; Young Deuk Choi; Yun Seob Song; Sung Joon Hong
Journal:  Oncol Lett       Date:  2013-08-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.